Medically reviewed by Dr. Tom Biernacki, DPM — Board-Certified Podiatric Surgeon — Balance Foot & Ankle, Howell & Bloomfield Hills, MI. Last updated April 2026.

GLP-1 receptor agonists — Ozempic, Wegovy, Mounjaro — are transforming diabetes and obesity treatment. As a podiatrist, I’m seeing the foot and ankle effects of this drug class in clinic regularly. Here’s what every patient on a GLP-1 drug should know about their feet.

The Rapid Weight Loss Effect on Feet

GLP-1 drugs produce rapid weight loss — often 15–25% body weight in the first year. For feet, this is mostly good news: less weight means less plantar fascia stress, less heel pain, and better glycemic control for diabetics. But the speed of change creates a transition problem.

When you lose 40–60 lbs rapidly, your foot volume changes significantly. Shoes that fit well before may now slip at the heel or cause new friction points. More critically, rapid weight loss in diabetics can temporarily worsen neuropathy symptoms as nerves begin regenerating — patients often report increased burning and tingling before improvement.

GLP-1 and Diabetic Foot: The Good News

Studies show semaglutide (Ozempic/Wegovy) reduces HbA1c by 1.5–2%, which translates to dramatically better foot wound healing, reduced neuropathy progression, and lower amputation risk in diabetic patients. The metabolic benefits for diabetic feet are real and significant.

The Muscle Loss Problem

GLP-1 drugs cause significant muscle mass loss alongside fat loss — studies suggest 30–40% of weight lost is lean mass. For feet, this means:

• Loss of the intrinsic foot muscles that support the arch
• Reduced calf muscle mass affecting ankle proprioception and Achilles tendon loading
• Increased fall risk from reduced lower extremity strength

The solution: Resistance training during GLP-1 treatment is critical — not optional. And for foot health specifically, foot-specific strengthening exercises (toe curls, short foot, calf raises) should be added to any GLP-1 protocol.

Ozempic Face vs. “Ozempic Feet”

You’ve heard of “Ozempic face” — the gaunt, hollow-cheeked appearance from rapid facial fat loss. The same mechanism affects the feet: rapid weight loss depletes the fat pads under the heel and ball of foot. These fat pads are natural shock absorbers; when they thin, patients experience new heel pain and ball-of-foot pain even as they lose weight. The fix: High-cushioning footwear (HOKA, New Balance Fresh Foam) and metatarsal pads during the weight loss phase.

What Podiatrists Should Do for GLP-1 Patients

If you’re on a GLP-1 drug, your podiatry care should include: monitoring foot fat pad thickness, adjusting orthotic prescriptions as your foot size changes, aggressive neuropathy monitoring during the weight loss phase, and resistance training referral if not already in place.

Frequently Asked Questions

Can Ozempic cure diabetic neuropathy?

Not directly. But by dramatically improving glycemic control, GLP-1 drugs slow neuropathy progression and allow some degree of nerve recovery. The foot symptoms often get temporarily worse before improving as nerves regenerate.

Will I need new orthotics after losing weight on GLP-1?

Likely yes, if you use custom orthotics. Significant weight loss changes foot structure, biomechanics, and shoe size. Most patients need orthotics reassessed after 40+ pounds of weight loss.

My feet hurt more since starting Ozempic — is this normal?

Temporarily increased foot pain during rapid weight loss can result from fat pad thinning, muscle loss, or neuropathic changes during nerve regeneration. If pain is new and worsening, see your podiatrist — don’t assume it will resolve on its own.

When to See a Podiatrist About GLP-1 and Foot Health

If you’re experiencing foot pain, changes in shoe fit, or new discomfort after starting GLP-1 medications like Ozempic, a board-certified podiatrist can diagnose the underlying cause and create a personalized treatment plan. At Balance Foot & Ankle, we offer comprehensive foot evaluations for patients on weight loss medications at our Howell and Bloomfield Hills offices.

→ Learn about our Foot Condition Evaluation options
→ Book your appointment
→ Call (810) 206-1402

Clinical References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
2. Messier SP, Gutekunst DJ, Davis C, DeVita P. Weight loss reduces knee-joint loads in overweight and obese older adults with knee osteoarthritis. Arthritis Rheum. 2005;52(7):2026-2032. doi:10.1002/art.21139
3. Hills AP, Hennig EM, Byrne NM, Steele JR. The biomechanics of adiposity — structural and functional limitations of obesity and implications for movement. Obes Rev. 2002;3(1):35-43. doi:10.1046/j.1467-789X.2002.00054.x

Dr. Tom Biernacki, DPM

Dr. Tom Biernacki, DPM is a double board-certified podiatrist and foot & ankle surgeon at Balance Foot & Ankle Specialists in Southeast Michigan. With over a decade of clinical experience, he specializes in heel pain, bunions, diabetic foot care, sports injuries, and minimally invasive surgery. Dr. Biernacki is a member of the APMA and ACFAS, and his patient education content on MichiganFootDoctors.com and YouTube has reached over one million views.